European Commission funds NUDZ·$0.22mLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bnEuropean Commission funds NUDZ·$0.22mLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bnEuropean Commission funds NUDZ·$0.22mLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bn
Next issueIssue 17 · Tue 6 Oct 

Molecules

MDMA

3,4-methylenedioxymethamphetamine

1 asset1 European trial record0 deals

Chemical class
benzodioxoles

Assets

European trials

Netherlands 1

Our calls

  • Issue 10OpenNo pharmaceutical company will be named as the responsible party on a BfArM compassionate use entry for psilocybin or MDMA before 31 December 2027. Our read, not anyone's stated plan.
  • Issue 8OpenNo psilocybin or MDMA therapy will enter a formal health technology assessment or benefit assessment process in Germany, the Netherlands or the United Kingdom before 31 December 2027. Our read, not anyone's stated plan.

Record history